Skip to content
Menu

Inhibrx Biosciences, Inc. INBX

Full chart Compare
Set alert

Price alert · INBX

All alert types
74.33 USD +5.27 (+7.63%)

Regular-session close

74.33 0.00 0.00%

After hours · Nov 19, 4:01 PM ET

69.49 Day range 80.65
57.30 52-week range 155.29
YTD
-5.91%
1 year
-9.51%

5D -10.12 (-11.98%)

70758085FriMonTueWedThu74.33
Market cap
1.10B
Revenue (ttm)
2.00M
EPS (ttm)
-9.06
Shares out
14.77M
Forward P/E
-8.71
YTD return
-5.91%
1-year return
-9.51%
50-day average
92.72
200-day average
92.58
Enterprise value
1.10B
Volume
420.89K
Avg volume
304.38K
Open
70.19
Previous close
69.06
Day's range
69.49 – 80.65
52-week range
57.30 – 155.29
Beta
4.04
Analysts
Strong Buy
Price target
258.33 (+247.5%)
Earnings date
Mar 18, 2027

Key statistics

Price / sales
548.89
Free cash flow
-81.11M
Total cash
199.47M
Total debt
281.44M
Short % of float
30.63%

Fundamental scorecard

4 of 25 checks passed on INBX’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 1 of 5
  • Growth 2 of 5
  • Profitability 0 of 5
  • Financial health 1 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
INBX Revenue — quarterly 2.00M
INBX Net income — quarterly -38.73M
INBX EPS — quarterly -2.46

Earnings

INBX recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 18, 2027Dec 30, 2026-2.57———
Nov 13, 2026Sep 30, 2026-2.45-2.46-0.01-0.41%
Aug 13, 2026Jun 30, 2026-2.28-2.34-0.06-2.63%
May 14, 2026Mar 31, 2026-2.37-2.15+0.22+9.28%
Mar 19, 2026Dec 31, 2025-2.08-2.11-0.03-1.44%
Nov 14, 2025Sep 30, 2025-2.08-2.28-0.20-9.62%

Upgrades / downgrades

INBX analyst upgrades and downgrades
DateFirmActionFromTo
Nov 16, 2026HC Wainwright & Co.mainBuyBuy
Aug 24, 2026HC Wainwright & Co.init—Buy
Apr 8, 2026Stifelinit—Buy
Aug 22, 2025JMP SecuritiesreitMarket PerformMarket Perform
May 15, 2025JMP SecuritiesreitMarket PerformMarket Perform
Mar 18, 2025Citizens Capital MarketsreitMarket PerformMarket Perform

About Inhibrx Biosciences, Inc.

Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma. Inhibrx Biosciences, Inc. was incorporated in 2024 and is based in La Jolla, California.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
inhibrx.com

News

Your note

Sign in to keep a note on INBX — it syncs with the Stock Master app.

Insider holders

INBX insider holders
InsiderRelationLatest transactionDateShares held
FORSYTH DOUGLASDirectorPurchaseSep 7, 20260
KAYYEM JON FAIZDirectorPurchaseSep 22, 20260
LAPPE MARKChief Executive OfficerPurchaseOct 13, 20260
MANHARD KIMBERLY JDirectorSaleSep 14, 20260
VIKING GLOBAL INVESTORS LPBeneficial Owner of more than 10% of a Class of SecuritySaleOct 6, 20250

Institution ownership

INBX institution ownership
Holder% heldSharesValueReported
Morgan Stanley8.94%1,320,66198.16MSep 29, 2026
Perceptive Advisors Llc8.75%1,292,46396.07MSep 29, 2026
Sanofi7.84%1,157,92686.07MSep 29, 2026
Viking Global Investors, L.P.7.50%1,108,00882.36MSep 29, 2026
HighTower Advisors, LLC5.99%884,44165.74MSep 29, 2026
Schonfeld Strategic Advisors Llc5.60%827,28061.49MSep 29, 2026

Fund ownership

INBX fund ownership
Holder% heldSharesValueReported
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund2.50%369,64127.48MJun 29, 2026
SmallCap World Fund Inc2.39%353,29226.26MSep 29, 2026
SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF2.20%324,79424.14MSep 29, 2026
iShares Trust-iShares Russell 2000 ETF1.68%247,83918.42MSep 29, 2026
VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund0.74%109,8838.17MJun 29, 2026
Fidelity Salem Street Trust-Fidelity Small Cap Index Fund0.70%103,9387.73MAug 30, 2026